Home     About SABCS     Press Releases     Media     Event Photos     Past Symposia     Satellite Symposia     Patient Advocates     FAQs     Contact Us



Registration           Hotel           Support & Exhibits     2014 Overview           Program           Travel & Transportation          

Quick Links
Career Development Forum Reg Form
SABCS 2013 Program Book pdf

Schedule at a Glance
 
Daily Schedule:
Tue. 12/10/2013
Wed. 12/11/2013
Thu. 12/12/2013
Fri. 12/13/2013
Sat. 12/14/2013
 
Poster Sessions:
Poster Session 1
Poster Session 2
Poster Session 3
Poster Session 4
Poster Session 5
Poster Session 6
 
Poster Session OT1
Poster Session OT2
Poster Session OT3
 
Poster Discussions:
Poster Discussion 1
Poster Discussion 2
Poster Discussion 3
Poster Discussion 4
Poster Discussion 5
Poster Discussion 6
 

Program Schedule   >  Poster Sessions - Poster Session 4

Poster Session 4 
   
  Detection and Diagnosis: Molecular, Functional, and Novel Imaging
P4-01-01 Serial FDG and 18F-fluoride PET predict response to therapy in patients with breast cancer bone metastases
Montgomery SK, Barlow WE, Linden HM, Gralow JR, Ellis GK, Gadi VK, Schubert EK, Peterson LM, Novakova A, Doot R, Dunnwald LK, Mankoff DA, Specht JM. University of Washington, Seattle, WA; Cancer Research and Biostatistics, Seattle, WA; University of Pennsylvania, Philadelphia, PA. Susan K. Montgomery is a recipient of an Avon-AACR International Scholar-In-Training Award
P4-01-02 The role of FLT PET early assessment of response to endocrine therapy for early stage breast cancer
Linden H, Kurland B, Link J, Novakova A, Chai X, Gadi V, Specht J, Hills D, Gralow J, Schubert E, Korde L, Peterson L, Doot R, Eary J, Shields A, Krohn K, Mankoff D. University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Seattle Cancer Care Alliance, Seattle, WA; University of Pennsylvania, Philadelphia, PA; University of Pittsburgh, Pittsburgh, PA.
P4-01-03 HDACi (vorinostat) in metastatic breast cancer to restore sensitivity to ER-directed (AI) therapy: A phase II clinical trial with FES imaging correlates
Linden H, Kurland B, Link J, Novakova A, Chai X, Specht J, Gadi V, Gralow J, Schubert E, Peterson L, Eary J, Shields A, Mankoff D, Krohn K. University of Washington, Seattle, WA; Fred Hutchison Cancer Research Center, Seattle, WA; Seattle Cancer Care Alliance, Seattle, WA; University of Pennsylvania, Philadelphia, PA; University of Pittsburgh, Pittsburgh, PA.
P4-01-04 Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer: Usefulness for malignant grade of triple-negative breast cancer
Ohara M, Hideo S, Akiko E, Masumoto N, Ozaki S, Kadoya T, Okada M. Hiroshima University, Hiroshima, Japan.
P4-01-05 3'-deoxy-3'-[18F]fluoro-thymidine (18F-FLT) positron emission tomography (PET): An accurate and effective tool for assessing tumor response in breast cancer
Couturier O, Rousseau C, Pierga J-Y, Berriolo-Riedinger A, Alberini J-L, Girault S, Fumoleau P, Brain E, Abadie-Lacourtoisie S, Vera P, Liehn J-C, Olivier P, Uwer L, Cachin F, Sagan C, Bouchet F, Lebas N, Mesleard C, Fourme E, Martin A-L, Lovinfosse P, Lacœuille F, Campone M. Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France.
P4-01-06 High resolution breast PET for monitoring response of breast cancer to neoadjuvant chemotherapy
Nelson JC, Lehde NL, Green CJ, Villanueva-Meyer J. Austin Cancer Centers, Austin, TX.
P4-01-07 Evaluation of FLT PET-CT as an imaging biomarker of proliferation in primary breast cancer
Woolf DK, Beresford M, Li SP, Sanghera B, Wong WL, Amin V, Ah-See M-L, Miles D, Sonoda L, Detre S, Dowsett M, Makris A. Academic Oncology Unit, Mount Vernon Cancer Centre, Northwood, United Kingdom; Royal United Hospital Bath, Bath, United Kingdom; Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, United Kingdom; Royal Marsden Hospital, London, United Kingdom.
P4-01-08 Assessing response in breast cancer with dynamic contrast enhanced magnetic resonance imaging: Are signal intensity time curves adequate?
Woolf DK, Padhani AR, Li SP, Beresford MJ, Jane Taylor N, Ah-See M-LW, Stirling J, Gogbashian A, Makris A. Academic Oncology Unit, Mount Vernon Cancer Centre, Northwood, United Kingdom; Royal United Hospital Bath, Bath, United Kingdom; Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, United Kingdom.
P4-01-09 18F-FLT-PET/CT for the prediction of response to ANG-1005 therapy in patients with brain metastases from breast cancer
Amiri-Kordestani L, Mena E, Lindenberg ML, Kurdziel K, Choyke P, Patronas N, Frye R, Lin N, Bala S, Fojo T, Bates S. National Cancer Institute, Bethesda, MD; Dana-Farber Cancer Institute, Boston, MA.
P4-01-10 Preoperative [18F]-fluoro-3'-deoxy-3'-L-thymidine positron emission tomography computed tomography (FLT-PET/CT) to predict early response to neoadjuvant chemotherapy in patients with primary breast cancer: Exploratory experience
Mariani G, Agresti R, Ricchini F, Bianchi GV, Capri G, Alessi A, Padovano B, De Braud F, Crippa F. Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
P4-01-11 Limits of [18F]-FLT PET as a clinical biomarker of proliferation in breast cancer
Schmidt EV, Blackman S, Iannone R, Senderak ET, Railkar RA, Evelhoch JL, Mozley PD, Perez EA, McDonough M, Rimawi M, Tolaney S, Kim S-B, Chung H-C. Merck Research Labs, Whitehouse Station, NJ; Seattle Genetics, Seattle, WA; Cornell Medical College, New York City, NY; Mayo Clinic Jacksonville, Jacksonville, FL; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Asan Medical Center, Seoul, Song-Pa, Korea; Yonsei University, Seoul, Seodaemun-gu, Korea.
P4-01-12 Optical imaging of breast density correlates with magnetic resonance imaging in patients undergoing neoadjuvant chemotherapy
O'Sullivan TD, Leproux A, Chen J-H, Bahri S, Matlock A, Roblyer D, McLaren CE, Chen W-P, Cerussi AE, Su M-Y, Tromberg BJ. University of California, Irvine, Irvine, CA; E-Da Hospital and I-Shou University, Yan-Chau Shiang, Kaohsiung, Taiwan.
P4-01-13 Fusion imaging using opto-acoustics and ultrasound to differentiate breast mass histopathology
Lavin P, Stavros AT, Tucker FL. Boston Biostatistics Research Foundation, Framingham, MA; Seno Medical Instruments, San Antonio, TX; Virginia Biomedical Laboratory, Wirtz, VA.
P4-01-14 Two-week change in optical tomography predicts residual cancer burden score in women treated with neoadjuvant chemotherapy
Lim EA, Gunther JE, Flexman M, Kim HK, Hibshoosh H, Kalinsky K, Crew K, Maurer M, Taback B, Feldman S, Ananthakrishnan P, Refice S, Brown M, Hielscher A, Hershman DL. Internal Medicine - Columbia University Medical Center, New York, NY; Herbert Irving Comprehensive Cancer Center, New York, NY; Biomedical Engineering - Columbia University, New York, NY; Philips Corporation, Tarrytown, NY; Columiba University, New York, NY; Epidemiology - Mailman School of Public Health, New York, NY; Columbia University Medical Center, New York, NY; Columbia University School of Nursing, New York, NY; Electrical Engineering – Columbia University, New York, NY.
P4-01-15 A high-throughput three-dimensional cell migration assay (BiO assay) for toxicity screening for breast cancer applications
Tseng H, Sabino LG, Haisler WL, Gage JA, Neeley SK, Souza GR. Nano3D Biosciences, Houston, TX; Rice University, Houston, TX; Physics Institute, São Carlos, University of São Paulo, São Carlos, SP, Brazil.
P4-01-16 The 3D telomeric profiling helps to subdivide luminal types of breast cancers in different sub groups
Samassekou O, Capellatti V, Musella V, Mai S. University of Manitoba, Manitoba Institute of Cell Biology, Winnipeg, MB, Canada; Experimental Oncology Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
P4-01-17 Molecular imaging and quantification of HER-2 status in metastatic breast cancer by using 68Ga-ABY-025/PET-CT
Lindman H, Carlsson J, Velikyan I, Feldwisch J, Lubberink M, Sandberg D, Sandström M, Tolmachev V, Wennborg A, Sörensen J. Uppsala University, Uppsala, Sweden; Biomedical Radiation Sciences, Uppsala University, Uppsala, Sweden; Affibody AB, Solna, Sweden.
P4-01-18 A discrete population of p63+/K5/14+ cells implicated in the pathogenesis of salivary gland-like tumors of the breast
Boecker W, Stenman G, Loening T, Andersson MK, Berg T, Buchwalow I. Institute for Hematopathology, Hamburg, Germany; Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden; Albertinen Pathology, Hamburg, Germany.
P4-01-19 Enhanced sensitivity to detect metastases of breast cancer to the lung and monitor response to inhibition of metastasis by IGF1R inhibitor using SWIFT MRI
Sachdev D, Idiyatullin D, Corum C, Weber J, Garwood M, Kobayashi N. Masonic Cancer Center University of Minnesota, Minneapolis, MN; Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN.
P4-01-20 Explore the differences and relationships between normal, ADH tissues and DCIS, IDC in breast by shell-isolated nanoparticle-enhanced Raman spectroscopy (SHINERS)
Zheng C, Han B, Zhang H, Liang L, Hu C, Xu W, Fan Z. The First Hospital of Jilin University, Changchun, Jilin, China; State Key Laboratory for Supramolecular Structure and Materials, Jilin University, Changchun, Jilin, China.
P4-01-21 Head to head comparison of standard echo doppler versus 3D speckle tracking echocardiography for early subclinical cardiotoxicity detection in breast cancer patients treated with anthracycline adjuvant chemotherapy
Arpino G, Galderisi M, De Angelis C, Milano M, Gargiulo P, Santoro A, De Stefano F, Muscariello R, De Santo I, Lauria R, De Simone G, De Placido S. University of Naples "Federico II", Naples, Italy; Cardiology, University of Naples "Federico II", Naples, Italy.
P4-01-22 Measurement of tumour lesion glycolysis by FDG-PET in triple negative breast cancer
Antony Tharayil I, Harada N, Patel N, Varghese V, Kenny L. Imperial College London, London, United Kingdom; Imperial College Healthcare NHS Trust, London, United Kingdom.
P4-01-23 MUC1 targeted MR imaging for the diagnosis and therapeutic response of breast cancer in mice model
Yuan S, Li H, Lv Y, Wang T, Ling R. XiJing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
P4-01-24 Positron emission mammography (PEM) does increase specificity in diagnosis of breast cancer
Müller FHH, Hentschel M, Müller AG, Farahati J. Radiology & Nuclear Medicine, Ludwigshafen, Germany; Department of Nuclear Medicine, Bern, Switzerland; Clinic for Radiology & Nuclear Medicine, Elisabeth-Hospital, Dorsten, Germany.
   
  Detection and Diagnosis: Radiology / Tumor Monitoring
P4-02-01 Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy using dynamic tomographic optical breast imaging (TOBI)
Sajjadi AY, Wanyo CM, Specht M, Schapira L, MOY B, Bardia A, Finkelstein DM, Boas DA, Carp SA, Isakoff SJ. Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA.
P4-02-02 Magnetic resonance spectroscopy based total choline estimation: Does it have a role in the differentiation of grade II breast cancers into high and low risk groups?
Makkat S, Schiettecatte A, Fierens Y, Carprieaux M, Vanhoey M, Fontaine C, Hoorens A, DeGreve J, DeMey J. Oncologisch Centrum UZ Brussel and Vrije Universiteit Brussel, Brussels, Belgium.
   
  Detection and Diagnosis: Detection and Diagnosis - Other
P4-03-01 Analysis of the impact of intraoperative margin assessment with adjunctive use of MARGINPROBE® vs. standard of care on margin status with different definitions of positive margin depth, results from a randomized prospective multi center study
Gittelman M. Coordinated Health, Allentown, PA.
P4-03-02 Mapping breast tissue types by miniature radio-frequency near-field spectroscopy sensor
Kaufman Z, Paran H, Haas I, Malinger P, Zehavi T, Karni T, Pappo I, Sandbank J, Diment J, Alweiss T. Meir Medical Center, Kfar Saba, Israel; Assaf Harofeh Medical Center, Zrifin, Israel; Kaplan Medical Center, Rehovot, Israel.
P4-03-03 Determination of lymph node status using the primary tumor's gene expression signature
Gyorffy B, Sztupinszki Z, Weltz B, Chen S-C, Quay S. Research Laboratory of Pediatrics and Nephrology, Budapest, Hungary; Atossa Genetics, Inc. and the National Reference Laboratory for Breast Health, Seattle.
P4-03-04 Computer extracted image measurements of nuclear shape and texture from H&E images appear to stratify low and high risk ER+ breast cancers assessed via oncotype DX
Madabhushi A, Doyle S, Basavanhally A, Gilmore H, Harris L, Shih N, Mies C, Feldman M, Tomaszewski J, Ganesan S. Case Western Reserve University, Cleveland, OH; Ibris Incorporated, Monmouth Junction, NJ; University of Pennsylvania, Philadelphia, PA; University at Buffalo, Buffalo, NY; Cancer Institute of New Jersey, New Brunswick, NJ.
P4-03-05 Characterization of circulating tumor cells identified by high definition assay in patients with benign and malignant breast disease
Lorizio W, Luttgen M, Marks J, Wilderman E, Bethel K, Kuhn P, Hwang S. Duke University Medical Center, Durham, NC; The Scripps Research Institute, La Jolla, CA.
P4-03-06 Initial ex-vivo study of the ability of an in situ fluorescence spectroscopy probe to distinguish benign from malignant breast tissues
Mathieu M-C, Moniz-Koum H, Vincent Y, Toullec A, Balleyguier C, Eyrignoux T, Vielh P, Chatellier F, Al Chab L, Fontaine-Aupart M-P, Farcy R, Delaloge S. Institut Gustave Roussy, Villejuif, France; Nodea Medical, Villejuif, France; Hôpital Privé d'Antony, Antony, France.
P4-03-07 The contribution of mammographic appearance, basal-like phenotype, and disease extent to prediction of breast cancer death
Smith RA, Wu WY-Y, Tabar L, Chen SL-S, Yen AM-F, Duffy SW, Tot T, Chiu SY-H, Fann JC-Y, Chen TH-H. American Cancer Society, Atlanta, GA; Graduate Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipai, Taiwan; Falun Central Hospital, Falun, Sweden; School of Oral Hygiene, Taipei Medical University, Taipai, Taiwan; Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom; Graduate Institute of Health Care Management, Chang Gung University, Taoyuan, Taiwan; Kainan University, Taoyuan, Taiwan.
P4-03-08 Pathological analysis of intraductal papillary lesions in 3690 patients
Xu Z, Xing W, Yang Z, Li Q, Gu Y, Zhang Y. The 3rd Clinical Medical College of Norman Bethune Health Science Center of Jilin University, Changchun, Jilin, China; The Ontario Cancer Institute, University Health Network, University of Toronto, Toronto, ON, Canada; Japan Union Hospital of Jilin University, Changchun, Jilin, China.
P4-03-09 Time points to diagnosis and treatment of invasive breast cancer in southwestern Ontario
Vandenberg TA, Ballantyne B, Diaz Rodriguez LA, Whiston FJ, Stitt LW. London Health Sciences Centre, London, ON, Canada; Western University, London, ON, Canada.
   
  Tumor Cell and Molecular Biology: Genomics
P4-04-01 Understanding estrogen receptor transcription in breast cancer
Carroll JS. Cancer Research UK, University of Cambridge, Cambridge, United Kingdom.
P4-04-02 RNA-seq reveals functional lncRNAs associated with estrogen-receptor status in breast cancer
Banerjee N, Chothani S, Kamalakaran S, Varadan V, Miskimen K, Vadodkar A, Abu-khalaf M, Sikov W, Harris LN, Dimitrova N. Philips Research North America, Briarcliff Manor, NY; Case Comprehensive Cancer Center, Cleveland, OH; Yale Comprehensive Cancer Center, Cleveland, OH; Warren Alpert Medical School of Brown University, Providence, RI; Seidman Cancer Center, Cleveland, OH.
P4-04-03 A microgenomic approach using LCM procured breast cancer cells to identify clinically relevant gene signatures that underlie favorable response of ILC to aromatase inhibitors
Sanders MA, Andres SA, Wittliff JL. University of Louisville, Louisville, KY.
P4-04-04 Targeted resequencing of germline PTEN-negative patients with Cowden disease reveals alternate mechanism of molecular alteration
Sevenet N, Gourdon S, Lafon D, Dupiot-Chiron J, Geneste G, Jones N, Bonnet F, Longy M. INSERM U916 & Oncogenetic Lab, Institut Bergonie, Bordeaux, France; Oncogenetic Lab, Institut Bergonie, Bordeaux, France; Plateforme Genome Transcriptome, Univ. Bordeaux Segalen, Bordeaux, France.
P4-04-05 Molecular subtyping reveals the heterogeneity of metaplastic breast cancers
Ng CKY, Weigelt B, Popova T, Mariani O, Stern M-H, Vincent-Salomon A, Reis-Filho JS. Memorial Sloan-Kettering Cancer Center, New York, NY; Institut Curie, Paris, France.
P4-04-06 Systematic analysis of molecular subgroups and age in patients with breast cancer
Liedtke C, Karn T, Gluz O, Becker S, Pusztai L, Holtrich U, Rody A. University Schleswig-Holstein Campus Luebeck, Luebeck, Germany; University Frankfurt, Frankfurt, Germany; Bethesda Moenchengladbach, Moenchengladbach, Germany; Yale University School of Medicine, New Haven.
P4-04-07 Heterogeneous gene fusions detected by RNASeq show enrichment of insulin signaling pathway genes in breast cancer
Varadan V, Agrawal V, Kamalakaran S, Banerjee N, Miskimen K, Vadodkar A, Abu-Khalaf M, Sikov W, Harris LN, Dimitrova N. Philips Research North America, Briarcliff Manor, NY; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Yale Comprehensive Cancer Center, New Haven, CT; Warren Alpert Medical School of Brown University, Providence, RI; Seidman Cancer Center, University Hospitals, Cleveland, OH.
P4-04-08 Genomic and transcriptomic characterization of papillary carcinomas of the breast
Piscuoglio S, Ng CKY, Martelotto LG, Cowell CF, Natrajan R, Bidard F-C, Wilkerson PM, Mariani O, Vincent-Salomon A, Weigelt B, Reis-Filho JS. Memorial Sloan-Kettering Cancer Center, New York, NY; The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France.
P4-04-09 Extensive novel hybrid isoforms revealed by RNA sequencing of 120 primary breast cancer samples
Kim J, Lee H-S, In Y-H, Moon H-G, Lee M, Lee JW, Kim MK, Kim J, You T, Lee E, Park J, Noh D-Y, Kim S, Han W. Seoul National University Hospital, Seoul, Korea; Macrogen Inc, Korea; Bioconvergence Research Center, Korea; Geference Inc, Korea.
P4-04-10 Clinically relevant tumor mutation profiles in patients with triple negative breast cancer (TNBC)
Kotoula V, Lilakos K, Timotheadou E, Dimopoulos MA, Christodoulou C, Pentheroudakis G, Gogas H, Charalambous E, Papadopoulou K, Gkakou C, Lakis S, Kalogeras KT, Pectasides D, Fountzilas G. Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece.
P4-04-11 Correlation study of gene polymorphisms on 19p13.1 with triple negative breast cancer
Xu Z, Xing H, Wang L, Zhou H, Gu Y. Breast Disease Institution of Jilin Province, Changchun, Jilin, China; Molecular Biology Center of Basic Medical Sciences College of Norman Bethune Health Science Center of Jilin University, Changchun, Jilin, China.
P4-04-12 Identification of a common genotype in patients (pts) with HER2-positive, ER-negative, inflammatory breast cancer (IBC) that was primary-refractory to trastuzumab who have had 5+ years of disease control with lapatinib therapy
O'Shaughnessy J, Levin M, Palmer G, Ross JS, Palma N, Yelensky R, Cao Y, Ramos C, Hoke G, Wang K. US Oncology Research, McKesson Specialty Health, The Woodlands, TX; Texas Oncology - Baylor Sammons Cancer Center, Dallas, TX; Foundation Medicine, Cambridge, MA; Theranostics Health, Rockville, MA.
P4-04-13 Could genes associated with response or resistance to radiotherapy be identified in breast cancer patients?
Mladenovic J, Susnjar S, Jankovic R, Tanic M, Radulovic S, Plesinac - Karapandzic V. Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
P4-04-14 A novel diagnostic method targeting genomic instability in breast intracystic tumors
Yano H, Oikawa M, Matsumoto M, Otsubo R, Shibata K, Hayashi T, Abe K, Kinoshita N, Nagayasu T. Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Kyushu, Japan; National Kyushu Cancer Center, Fukuoka, Kyushu, Japan; Nagasaki University Hospital, Nagasaki, Kyushu, Japan.
P4-04-15 UC San Diego molecular tumor board: Experience in breast cancer
Parker BA, Schwab RB, Helsten TL, Sarah BG, Ojeda-Fournier H, Datnow B, Schwaederle MC, Coutinho AC, Kurzrock R. UC San Diego Moores Cancer Center, La Jolla, CA; UC San Diego School of Medicine, La Jolla, CA.
P4-04-16 Highly variably expressed exons (HVEE) of cancer genes and survival disparity in human breast cancer
Li R, Campos J, Chen Y, Kvecher L, Gdula D, Hoadley KA, Shriver CD, Mural RJ, Hu H. Windber Research Institute, Windber, PA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD.
   
  Tumor Cell and Molecular Biology: Molecular Profiles
P4-05-01 lncRNA signature defines subtypes in breast cancer
SU X, Malouf G, Chen Y, Esteva F. MD Anderson Cancer Center; Groupe Hospitalier Pitie-Salpetriere, University Pierre and Marie Curie (Paris VI).
P4-05-02 Phospho-reactome measurements reveal heterogenic kinase signatures
Coppé J-P, Chen Z, Mori M, Boudreau A, van 't Veer L. University of California San Francisco, San Francisco, CA; Kinogea Inc., Moraga, CA.
P4-05-03 Unique genetic, epigenetic, and transcriptomic changes in premenopausal breast cancer suggest novel strategies for therapy
Liao G, Hartmaier RJ, Luthra S, Chandran U, McGuire KP, Puhalla SL, Lee AV, Tseng GC, Oesterreich S. University of Pittsburgh, Pittsburgh, PA; University of Pittsburgh Cancer Institute, Magee Womens Research Institute, Pittsburgh, PA; University of Pittsburgh Cancer Institute, UPMC Cancer Center, Pittsburgh, PA.
P4-05-04 Proteomic patterns unravel a new luminal-A breast cancer molecular subgroup with prognostic value
Espinosa E, Berges-Soria J, Gamez-Pozo A, Nanni P, Grossmann J, Lopez-Vacas R, Castaneda CA, Diaz-Almiron M, Madero R, Zamora P, Ciruelos E, Fresno-Vara JA. Hospital La Paz - IdiPAZ, Madrid, Spain; Laboratory of Molecular Oncology & Pathology, INGEMM - IdiPAZ, Madrid, Spain; Functional Genomics Centre, Zürich, Switzerland; Hospital Doce de Octubre - i+12, Madrid, Spain; IdiPAZ, Madrid, Spain.
P4-05-05 Molecular effects of initial core biopsies in neoadjuvant window studies
Arthur LM, Turnbull AK, Renshaw L, Sabine VS, Bartlett JM, Sims AH, Dixon JM. Breakthrough Breast Cancer Research Unit, Edinburgh, United Kingdom.
P4-05-06 Host inflammation and breast cancer molecular subtypes: Updated results from a TCGA sub-analysis
Allison KH, Chen Y-Y, Jensen KC, Sanders ME, Reis-Filho J, Lester SC, Johnson NB, Factor RE, Tse GMK, Shin SJ, Eberhard DA, Tan PH, Collins LC, Korski K, Waldman FM, Perou CM, Beck AH. Cancer Genome Atlas (TCGA) Breast Cancer Expert Pathology Committee, Bethesda, MD.
P4-05-07 Molecular profiles of screen detected breast cancers: Final results of Turkish Bahcesehir breast cancer screening project
Cabioglu N, Ozkan-Gurdal S, Kayhan A, Ozaydin N, Ozcinar B, Aribal E, Ozmen V. Faculty of Medicine, Acibadem University, Istanbul, Turkey; Faculty of Medicine, Namik Kemal University, Tekirdag, Turkey; Marmara University, Istanbul, Turkey; Faculty of Medicine, Marmara University, Istanbul, Turkey; Faculty of Medicine, Istanbul University, Istanbul, Turkey.
P4-05-08 Oncotype Dx assay in BRCA positive ER positive breast cancer patients
Halpern N, Sonnenblick A, Kaduori L, Uziely B, Goldberg Y, Katz D, Allweis T, Divinsky L, Merlet I, Maly B, Sagi M, Hamburger T, Carmon E, Peretz T. Sharette Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Hadassah Hebrew University Medical Center, Jerusalem, Israel; Sarah Markowitz Breast Center, Kaplan Medical Center, Rehovot, Israel.
P4-05-09 Estrogen receptor (ER) mRNA expression and molecular subtype distribution in breast cancers that are ER-negative but progesterone receptor-positive by immunohistochemistory
Iwamoto T, Matsuoka J, Nogami T, Motoki T, Shien T, Taira N, Niikura N, Hayashi N, Doihara H, Symmans W, Pusztai L. Okayama University, Okayama, Japan; Tokai University; St Luke's International Hospital; Yale University Cancer Center; The University of Texas MD Anderson Cancer Center.
P4-05-10 PIK3CA mutations are enriched in invasive lobular carcinomas and invasive mammary carcinomas with lobular features: Results from a TCGA sub-analysis
Sanders ME, Allison KH, Chen Y-Y, Lester SC, Johnson NB, Factor RE, Tse GMK, Shin SJ, Eberhard DA, Tan PH, Perou CM, Collins LC, Jensen KC, Korski K, Waldman FM, Reis-Filho J, Knoblauch NW, Beck AH. Cancer Genome Atlas (TCGA) Breast Cancer Expert Pathology Committee, Bethesda, MD.
P4-05-11 A proteasomal signature of breast cancer cells
Gaczynska M, Mueller B, Rodriguez KA, Osmulski PA. University of Texas Health Science Center at San Antonio, San Antonio, TX.
P4-05-12 MultiOmyx™ screening for prognostic indicators of breast cancer
LaPlante N, Shang S, Santa-Maria Pang A, Dinn S, Kaanumalle S, McDonough E, Lowes C, Sui Y, Gerdes M, Ginty F. GE Global Research, Niskayuna, NY.
P4-05-13 Withdrawn
P4-05-14 Molecular and immunohistochemical profile of invasive micropapillary breast carcinoma
Thomas A, Askeland RW, Guseva NV, Sompallae R, Ma D. University of Iowa Hospitals and Clinics, Iowa City, IA.
P4-05-15 Breast cancers with BRCA1 and BRCA2 mutations are associated with specific pathologic features and molecular profiles: Results from a TCGA sub-analysis
Chen Y-Y, Allison KH, Lester SC, Collins LC, Eberhard DA, Factor RE, Jensen KC, Johnson NB, Korski K, Reis-Filho JS, Sanders ME, Shin SJ, Tan PH, Tse GMK, Waldman FM, Knoblauch NW, Perou CM, Beck AH. Cancer Genome Atlas (TCGA) Breast Cancer Expert Pathology, Bethesda, MD.
P4-05-16 Quality metric study of real-time targeted massive parallel sequencing (MPS) (ampliseq comprehensive cancer panel (CCP)) and bioinformatics in early breast cancer (EBC) using life technologies ion proton system
Mainwaring PN, Pyke C, Korbie D, Pheasant M, O'Neill K, Musgrave K, Phillips C, Francis G, Trau M. Haematology & Oncology Clinics of Australia, Brisbane, Queensland, Australia; University of Queensland, Brisbane, Queensland, Australia.
P4-05-17 Withdrawn
   
  Tumor Cell and Molecular Biology: Tumor Heterogeneity / Molecular Subclassification
P4-06-01 Expression and DNA copy number profiling suggest novel therapeutic approaches for triple negative breast cancer subtypes
Burstein MD, Tsimelzon A, Hilsenbeck SG, Fuqua SW, Chang JC, Osborne CK, Mills GB, Brown PH, Lau CC. Structural and Computational Biology & Molecular Biophysics Graduate Program; Lester and Sue Smith Breast Center; Department of Molecular and Cellular Biology; Baylor College of Medicine, Houston, TX; Department of Systems Biology; MD Anderson Cancer Center, Houston, TX.
P4-06-02 Changes in intrinsic subtype of breast cancer during tumor progression in same patient
Kim C, Kim A. Korea University Guro Hospital, Guro Gu Guro Dong, Seoul, Republic of Korea.
P4-06-03 Assays on core biopsies and surgically resected tumors may result in different subtyping of the invasive breast cancer from the same patient
Kovatich AJ, Chen Y, Fantacone-Campbell JL, Wareham JA, Tafra L, Kvecher L, Hyslop T, Hooke JA, Rui H, Shriver CD, Mural RJ, Hu H. Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; Biomedical Informatics, Windber Research Institute, Windber, PA; Breast Center, Anne Arundel Medical Center, Annapolis, MD; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
P4-06-04 Effect of genomic heterogeneity on breast cancer progression and metastatic spread
Ellsworth RE, Valente AL, Blackburn HL, Decewicz A, Deyarmin B, Mamula K, Shriver CD, Ellsworth DL. Henry M. Jackson Foundation; Windber Research Instittute; Walter Reed National Military Medical Center.
P4-06-05 Transcriptional heterogeneity correlates with chemotherapy sensitivity in triple negative breast cancer and varies by molecular subtype
Jiang T, Shi W, Ononye S, Han G, Wali V, Pusztai L, Hatzis C. Yale University Cancer Center, New Haven, CT.
P4-06-06 Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea
Park YH, Kil WH, Lee JE, Nam SJ, Ahn JS, Im Y-H. Samsung Medical Center.
P4-06-07 Withdrawn
P4-06-08 Withdrawn
P4-06-09 HER2+ and HER2- luminal B subtypes have similar overall survival and histologic grade distributions
Chen Y, Kovatich AJ, Fantacone-Campbell JL, Hooke JA, Kvecher L, Kovatich AW, Gallagher CM, Hueman MT, Hyslop T, Mural RJ, Shriver CD, Rui H, Hu H. Biomedical Informatics, Windber Research Institute, Windber, PA; Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; MDR Global Systems, Windber, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
P4-06-10 Breast cancer subtypes in Indian women: A comparison of clinicopathological features and outcome
Mane AD, Deshmukh SP, Nag SM, Guha A, Sane SP, Zade BP. Ruby Hall Clinic, Pune, Maharashtra, India.
P4-06-11 HER2 type DCIS acquires histological diversity by p53 mutation
Kamio M, Nogi H, Mimoto R, Imawari Y, Kato K, Uchida K, Takeyama H. Jikei University, School of Medicine, Tokyo, Japan.
P4-06-12 Simultaneous phenotypic and genotypic heterogeneity at the cellular level approached by HER2 gene-protein assay (GPA) in the invasive ductal carcinoma of the breast: A new approach for cancer pathobiology
Osamura RY, Kuwayama A, Katoh M. International University of Health and Welfare Mita Hospital, Tokyo, Japan.
P4-06-13 Discovering serum biomarkers for predicting accumulation of nanotherapeutics to different tumor and organ microenvironments
Yokoi K, Tanei T, Godin B, van de Ven AL, Alexander J, Saito Y, Ferrari M. The Methodist Hospital Research Institute, Houston, TX.
   
  Tumor Cell and Molecular Biology: MicroRNAs
P4-07-01 Upregulation of miR-224 in breast cancer exhibiting hyperactivation of ERK1/2 MAPK signaling associates with repression of Raf kinase inhibitory protein and poor clinical outcome
Miller P, Lairet S, El-Ashry D. University of Miami, Miami, FL.
P4-07-02 MicroRNA 204 mediated negative regulation of the IGF2R promotes breast cancer progression and is a potential mechanism driving breast cancer disparity
Findlay VJ, Nogueira LM, Turner DP, Kramer RM, Rosenzweig SA, Rosen JM, Watson DK. Medical University of South Carolina, Charleston, SC; Baylor College of Medicine, Houston, TX.
P4-07-03 Fibroblasts-myofibroblasts transition induced by miR-21 determines the malignancy of breast phyllodes tumors
Nie Y, Gong C, Su F, Zeng Y, Qu S, Liu Q, Song E. Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
P4-07-04 A distinctive miRNA profile highlights breast cancer in very young women (BCVY) as a new molecular subgroup
Peña-Chilet M, Martinez MT, Perez-Fidalgo JA, Peiro-Chova L, Bermejo B, Ferrer J, Alonso E, Burgues O, Bosch A, Lluch A, Ribas G. INCLIVA Biomedical Research Institute, Valencia, Spain; Memorial Sloan-Kettering Cancer Center, New York, NY.
P4-07-05 Cyclin D1 induction of dicer governs microRNA processing and expression in breast cancer
Pestell RG, Yu Z, Wang L, Wang C, Ju X, Wang M, Chen K, Loro E, Wu K, Casimiro MC, Gormley M, Ertel A, Fortina P, Chen Y, Tozeren A, Liu Z. Thomas Jefferson University, Philadelphia, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China; Center for Integrated Bioinformatics, Drexel University, Philadelphia, PA; School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA.
P4-07-06 Withdrawn
P4-07-07 Analysis of miRNAs and proteins relations in breast cancer
Ciruelos EM, Gámez-Pozo A, Nanni P, Berges-Soria J, Navarro H, Lopez-Vacas R, Arevalilllo J, Castañeda C, Grossmann J, Pascual T, de Velasco G, Diaz-Almiron M, Madero R, Main P, Espinosa E, Fresno JA. University Hospital 12 de Octubre, Madrid, Spain; Molecular Oncology Lab. INGEMM, Instituto IdiPAZ, Madrid, Spain; Functional Genomics Centre Zürich, University of Zürich, Zurich, Switzerland; University Nacional Educacion a Distancia (UNED), Madrid, Spain; Instituto de Enfermedades Neoplásicas, Lima, Peru; Instituto de Investigación Hospital La Paz-IdiPAZ, Madrid, Spain; Faculty of Mathematic, Complutense University of Madrid, Madrid, Spain; Instituto de Investigación Hospital La Paz-IdiPAZ., Madrid, Spain.
P4-07-08 The predictive and prognostic role of tumoral miRNA expression levels in patients with breast cancer (BC) treated with neoadjuvant chemotherapy (NAC)
Eralp Y, Keskin S, Gezer U, Tukenmez M, Muslumanoglu M, Dalay N, Disci R, Yavuz E, Igci A. Istanbul University, Oncology Institute, Istanbul, Capa, Turkey; Okmeydani Research and Education Hospital, Istanbul, Sisli, Turkey; Istanbul University, Istanbul Medical Faculty, Istanbul, Capa, Turkey.
P4-07-09 An approach to the identification of tumors driven by HER2 using the integrated activity of oncomiR miR-21 along with HER2 enriched genes
Kaul R, Prabhu JS, Swaminath S, Korlimarla A, Correa M, Prasad M, Manjunath S, Gopinath K, Swami S, Shastry SB, Sridhar T. St. John's Research Institute, Bangalore, Karnataka, India; St. John's Medical College and Hospital, Bangalore, Karnataka, India; St. John's Medical College, Bangalore, Karnataka, India; Rangadore Memorial Hospital, Bangalore, Karnataka, India; Indian Institute of Science, Bangalore, Karnataka, India; Sri Shankara Cancer Hospital and Research Centre, Bangalore, Karnataka, India. Roma Kaul is a recipient of an Avon-AACR International Scholar-In-Training Award
P4-07-10 MicroRNAs as biomarkers and therapeutic adjuvants for the prognosis and treatment of drug-resistant breast cancers
Chang Y-F, Pannerdoss S, Zoghi B, Jatoi I, Rao MK. UT Health Science Center at San Antonio, San Antonio, TX.
P4-07-11 Dual characteristics of microRNA-484 modulated cytidine deaminase (CDA) axis in breast cancer: Chemo-resistance and regulating cell proliferation
Hu X, Ye F, Cao Z, Ling H, Qiao F, Song C, Shao Z. Shanghai Cancer Center, Fudan University, Shanghai, China; Fujian Medical University, Fuzhou, Fujian, China.
P4-07-12 miR-206 inhibits cell migration through direct targeting of the actin-binding protein coronin 1C in triple-negative breast cancer
Wang J, Tsouko E, Jonsson P, Bergh J, Hartman J, Aydogdu E, Williams C. Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, TX; Karolinska Institutet and University Hospital, Stockholm, Sweden.
P4-07-13 High microRNA-621 level predicts a better response to neoadjuvant chemotherapy in breast cancer patients
Xue J, Chen Y, Chi Y, Ye X, Wu Z, Wu J. Fudan University Shanghai Cancer Center, Shanghai, China; Institut Meárieux Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China; Shanghai Medical College, Fudan University, Shanghai, China; First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, China; University of Tennessee Health Science Center, Memphis, TN; Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN. Jingyan Xue is a recipient of an Avon-AACR International Scholar-In-Training Award
P4-07-14 The effects of calorie restriction on microRNA expression profiles and DMBA-induced mammary tumorigenesis in a model of luminal A breast cancer
Devlin KL, Sanford T, Mambo E, Hursting SD. University of Texas at Austin, Austin, TX; Asuragen Inc, Austin, TX; UT-MD Anderson Cancer Center, Smithville, TX.
P4-07-15 Prognostic impact of miR-18a expression in residual tumor after neoadjuvant chemotherapy for locally advanced breast cancer
Luengo-Gil G, González-Conejero R, Chaves-Benito A, Soler-Sánchez G, González-Billalabeitia E, Pérez-Henarejos S, García-Martínez H, Arroyo-Rodríguez A, Vicente V, Ayala-de la Peña F. University Hospital Morales Meseguer, Murcia, Spain; University of Murcia, Murcia, Spain.
P4-07-16 Expression profiles of miRNAs in breast cancer: Histologic type and patient race
Putcha B-DK, Jadhav T, Bovell LC, Hebert-Magee S, Frost A, Eltoum I-E, Bae S, Manne U. University of Alabama, Birmingham, AL.
P4-07-17 Identification of novel miRNAs differntially regulated by breast cancer amplified sequence 2 and follistatin in breast cancer cells
Sengupta D, Bhargava DK, Kumari K, Mishra SK. Institute of Life Sciences, Bhubaneswar, Odisha, India.
P4-07-18 PDGFRbeta-induced miR-9 is up-regulated in triple negative breast cancer
Plantamura I, D'Ippolito E, Tessari A, Cresta S, Orlandi R, Moliterni A, Carcangiu ML, De Braud F, Tagliabue E, Iorio MV. Start Up Unit, Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
P4-07-19 MicroRNA miR-24 enhances tumor angiogenesis and metastasis in breast cancer
Xu Z, Wang X, Fang L. Breast Disease Institution of Jilin Province of China, Changchun, Jilin, China; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Tornoto, ON, Canada.
   
  Epidemiology, Risk, and Prevention: Prevention - Behavioral Interventions
P4-08-01 Effects of exercise during adjuvant chemotherapy on clinical outcomes in early stage breast cancer
Courneya KS, Segal RJ, McKenzie DC, Dong H, Gelmon K, Friedenreich CM, Yasui Y, Reid RD, Crawford JJ, Mackey JR. University of Alberta, Edmonton, AB, Canada; Ottawa Hospital Regional Cancer Center, Ottawa, ON, Canada; University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Alberta Health Services, Calgary, AB, Canada; University of Ottawa Heart Institute, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada.
P4-08-02 Association of emotional disorders with the physical exercising habits among hospital discharged breast cancer patients in Hong Kong
Chen J, Liu P, Sun Y. The University of Hong Kong, Hong Kong, Hong Kong.
P4-08-03 Evaluating the opportunity and need for communicating breast cancer risk reduction messages to US women
Weiss M, Hebard A, Boffetta P. Breastcancer.org, Ardmore, PA; Lankenau Medical Center, Wynnewood, PA; Hebard Research Services, Maplewood, NJ; Ichan School of Medicine at Mount Sinai, New York, NY.
   
  Epidemiology, Risk, and Prevention: Prevention - Nutritional Studies
P4-09-01 Impact of adherence to guidelines on nutrition and physical activity for breast cancer prevention in high-risk women
Chehayeb Makarem D, Reimers L, Greenlee H, Terry MB, Whiffen A, Crew K. Columbia University Medical Center, New York, NY.
P4-09-02 Omega-3 ethyl esters suppress breast cancer growth by modulating inflammatory signaling
Chen CH, Quach D, Bowers L, Fabian C, Hursting S, deGraffenried L. The University of Texas at Austin, Austin, TX; The University of Kansas Cancer Center, Kansas City, KS.
P4-09-03 A diet enriched by soy-derived isoflavones impacts on the development of premalignant stages of breast cancer in an estrogen driven carcinogenesis animal model
Moeller FJ, Raffaelli F, Zierau O, Muders M, Soukup S, Kulling S, Vollmer G. Technische Universität Dresden, Institute for Zoology; Molecular Cell Physiology and Endocrinology, Dresden, Saxony, Germany; University Hospital Carl Gustav Carus, Institute of Pathology, Dresden, Saxony, Germany; Max Ruber Institut, Sicherheit und Qualität bei Obst und Gemuese, Karlsruhe, Baden-Württemberg, Germany.
P4-09-04 Weight loss and lipid-lowering efficacy of a low carbohydrate, calorie restricted diet intervention on postmenopausal breast cancer patients
Krie AK, Bohlen KN, Demuth H, Ageton C, Norfolk D, Kittelsrud J, Thomes R, Fahrendorf A, Muth J, Rojas-Espaillat LA, Davies GE, Hu Y. Avera Cancer Institute, Sioux Falls, SD; Avera Research Institute, Sioux Falls, SD; University of South Dakota, Sioux Falls, SD.
P4-09-05 Preventive efficacy of the Chinese nutritional herb epimedium grandiflorum in a preclinical cell culture model for luminal A molecular subtype of breast cancer
Telang NT, Li G, Katdare M, Sepkovic DW, Bradlow LH, Wong GYC, Telang N. Palindrome Liaisons Consultants, Montvale, NJ; American Foundation for Chinese Medicine, New York, NY; Hampton University, Hampton, VA; Hackensack University Medical Center, Hackensack, NJ.
P4-09-06 No inverse association between breast cancer risk and n-3 unsaturated fatty acids in erythrocytes among Japanese women
Koriyama C, Kijima Y, Natsugoe S, Akiba S. Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
P4-09-07 Mango (Mangifera Indica L. Var Keitt) polyphenols reduced inflammation in MDA-MB231 breast cancer cell: Possible role of miR-21/PTEN/AKT
Arbizu S, Krenek K, Mertens-Talcott S. Texas A&M University, College Station, TX
   
  Epidemiology, Risk, and Prevention: Prevention - Clinical Trials
P4-10-01 High dose omega-3 fatty acid supplementation modulates breast tissue biomarkers in post-menopausal women at high risk for development of breast cancer
Fabian CJ, Kimler BF, Petroff BK, Zalles CM, Metheny T, Nydegger JL, Box JA, Phillips TL, Hidaka BHH, Carlson SE, deGraffenried LA, Hursting SD. University of Kansas Medical Center, Kansas City, KS; Mercy Hospital, Maimi, FL; University of Texas, Austin, TX.
   
  Epidemiology, Risk, and Prevention: Prevention - Preclinical Studies
P4-11-01 Effect of letrozole is superior to tamoxifen in limiting preneoplasia in both ERα and aromatase over-expressing mice
Diaz-Cruz ES, Dabydeen SA, Al-kharboosh R, Wang W, Furth PA. Belmont University, Nashville, TN; Georgetown University, Washington, DC.
P4-11-02 Mammary tumor formation induced by N-methyl-N-nitrosourea (MNU) is accelerated by natural and synthetic progesterone but suppressed by an anti-progesterone CDB4124
Lee O, Sullivan M, Ivancic D, Shidfar A, Wiehle R, Khan SA. Northwestern University, Chicago, IL; Repros Therapeutics, The Woodlands, TX.
P4-11-03 Effect of tamoxifen and raloxifene on proliferative activity of breast epithelium in premenopausal women
Freitas-Junior R, Lucato MT, Moreira MA, Bernardes-Junior JM, Pinto SA, Paulinelli RR, Soares LR. School of Medicine, Federal University of Goias, Goiania, Goias, Brazil; Service of Mastology, Santa Casa de Misericordia Hospital, Goiania, Goias, Brazil.
P4-11-04 Targeted vaccination against human α-lactalbumin may provide immunotherapy and immunoprevention of triple negative breast cancer
Tuohy VK, Jaini R, Johnson JM, Mazumder S, Crowe J, Budd GT. Cleveland Clinic, Cleveland, OH.
   
  Treatment: HER2-Targeted Therapy
P4-12-01 Molecular features and survival outcomes of the intrinsic subtypes of breast cancer based on HER2 gene amplification
Prat A, Carey LA, Adamo B, Vidal M, Perou CM, Baselga J, Cortés J. Vall d´Hebron Institute of Oncology (VHIO); University of North Carolina at Chapel Hill; Memorial Sloan-Kettering Cancer Center.
P4-12-02 High HER2 gene amplification and clinical outcomes in localized HER2-positive breast cancer
Reynolds KL, Sasmit S, Moy B, Elena B, Amy C, Atul B, Aditya B. Massachusetts General Hospital, Boston, MA.
P4-12-03 Role of primary tumor molecular characteristics in identifying relapses in HER2-positive breast carcinomas adjuvantly treated with trastuzumab
Triulzi T, De Cecco L, Giussani M, Canevari S, Carcangiu ML, Menard S, Campiglio M, Tagliabue E. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Functional Genomics Core Facility, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
P4-12-04 Initial treatment and survival among elderly breast cancer patients by receipt of human epidermal growth factor receptor 2-targeted therapy: An analysis of US national data 2006-2009
Hao Y, Lang K, Huang H, Federico V, Rogerio JW, Menzin J. Novartis Pharmaceuticals Corporation, East Hanover, NJ; Boston Health Economics, Inc., Waltham, MA.
P4-12-05 Withdrawn
P4-12-06 Small HER2-positive breast carcinomas: Prognostic factors to consider in deciding on adjuvant trastuzumab treatment
Campiglio M, Sandri M, Sasso M, Bianchi F, Turdo F, Ménard S, Tagliabue E, On Behalf of the GHEA Group. Fondazione IRCCS-Istituto Nazionale dei Tumori, Milan, Italy.
P4-12-07 Neoadjuvant trastuzumab emtansine and docetaxel, with or without pertuzumab, in patients with HER2-positive early-stage breast cancer: Results from a phase 1b/2a study
Martin M, Dewar J, Albanell J, Limentani S, Chang J, Strasak A, Patre M, Garcia-Sáenz JA. Hospital General University Gregorio Maranon, Madrid, Spain; Ninewells Hospital, Dundee, United Kingdom; Hospital del Mar, Barcelona, Spain; Levine Cancer Institute, Charlotte, NC; Methodist Cancer Center, Houston, TX; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Hospital Clinico San Carlos, Madrid, Spain.
P4-12-08 Final efficacy results from a single-arm multicenter phase II study evaluating first-line trastuzumab, bevacizumab, and capecitabine (HAX) therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)
Martín M, Makhson A, Gligorov J, Lichinitser M, Lluch A, Semiglazov V, de Ducla S, Mitchell L, Tjulandin S. Hospital Gregorio Maranon, Universidad Complutense, Madrid, Spain; Moscow Oncological Hospital No. 62, Moscow, Russian Federation; APHP Tenon, APREC, University Cancer Institute-Paris VI Sorbonne University, Paris, France; NN Blokhin Russian Cancer Research Center, Moscow, Russian Federation; Hospital Clinico de Valencia, INCLIVA, Universidad de Valencia, Valencia, Spain; NN Petrov Research Institute of Oncology, St Petersburg, Russian Federation; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
P4-12-09 Results from a phase 2a study of trastuzumab emtansine, paclitaxel, and pertuzumab in patients with HER2-positive metastatic breast cancer
Elias A, Modi S, Krop IE, Pegram M, Ipe D, Guardino EA, Althaus B, LoRusso PL. University of Colorado Hospital, Auriora, CO; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; Stanford Cancer Institute, Palo Alto, CA; Genentech, Inc., South San Francisco, CA; Karmanos Cancer Institute, Detroit, MI.
P4-12-10 Safety of pertuzumab (P) with trastuzumab (T) and docetaxel (D) in patients (pts) from Asia with HER2-positive metastatic breast cancer (MBC): Results from the phase III trial CLEOPATRA
Swain SM, Im Y-H, Im S-A, Miles D, Knott A, Clark E, Ross G, Baselga J. MedStar Washington Hospital Center, Washington; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University College of Medicine, Seoul, Korea; Mount Vernon Cancer Centre, Middlesex, United Kingdom; Roche Products Limited, Welwyn, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York.
P4-12-11 Patient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive early breast cancer: Cohort 2 of the PrefHer study
Pivot X, Gligorov J, Müller V, Verma S, Knoop A, Curigliano G, Camci C, Jenkins V, Scotto N, Osborne S, Fallowfield L. CHU Jean Minjoz, Besançon, France; APHP-Tenon IUC-UPMC, Paris, France; University Medical Center, Hamburg, Germany; Sunnybrook Odette Cancer Centre, Toronto, Canada; Copenhagen University Hospital, Copenhagen, Denmark; European Institute of Oncology, Milan, Italy; Gaziantep Oncology Hospital, Gaziantep, Turkey; Sussex Health Outcomes, Research & Education in Cancer (SHORE-C), University of Sussex, Falmer, Brighton, United Kingdom; F. Hoffmann-La Roche Ltd, Basel, Switzerland
P4-12-12 Phase 2, multicenter, single-arm study of eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer
Wilks S, Puhalla S, O'Shaughnessy J, Schwartzberg L, Berrak E, Song J, Rege J, Cox D, Vahdat L. US Oncology - Cancer Care Centers of South Texas, San Antonio, TX; Magee Womens Hospital, Pittsburgh, PA; Texas Oncology-Baylor Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Eisai Inc., Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY.
P4-12-13 Withdrawn
P4-12-14 Metal chelating polymer-conjugated trastuzumab labeled to high specific activity with indium-111 is cytotoxic to trastuzumab-sensitive and resistant breast cancer cells through the emission of auger electrons
Ngo Ndjock Mbong G, Lu Y, Chan C, Cai Z, Winnik MA, Reilly RM. University of Toronto, Toronto, ON, Canada; Toronto General Research Institute, University Health Network, Toronto, ON, Canada.
P4-12-15 Long term outcome with trastuzumab in HER2-positive metastatic breast cancer: A retrospective analysis at The Royal Marsden Hospital, with a median 6 years follow up
Yeo BJ, Kotsori K, Johnston SRD, Smith I. Royal Marsden Hospital, London, United Kingdom.
P4-12-16 Safety profile and costs of related adverse events of trastuzumab emtansine compared to other regimens in the Canadian health care system
Piwko C, Yunger S, Moser A, Peter L, Vicente C. PIVINA Consulting Inc, Mississauga, ON, Canada; Centre de Sante et du Service Sociaux Champlain-Charles-Le Moyne, Greenfileld Park, QC, Canada; Hoffmann-La Roche Limited, Mississauga, ON, Canada; F. Hoffmann - La Roche AG, Basel, Switzerland.
P4-12-17 Pathological responses and heart safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy in clinical stage II-III, HER2-positive breast cancer patients: A phase 2, open-label, multicentre, randomised trial
Huang L, Chen S, Yang W, Xu B, Huang T, Yang H, Zheng H, Wang Y, Song E, Zhang J, Cui S, Pang D, Tang L, Lei Y, Geng C, Shao Z. Fudan University Shanghai Cancer Center/Cancer Institute, Shanghai, China; Shanghai Medical College, Fudan University, Shanghai, China; Union Hosptial Tongji Medical Colleage Huazhong University of Science and Technology, Wuhan; Cancer Institute&Hospital, Chinese Academy of Medical Sciences, Beijing; Zhejiang Cancer Hospital, Hangzhou; West China School of Medical, West China Hospital, Sichuan University, Chengdu; Shang Dong Cancer Hosptial, Jinan; The Second Affiliated Hospital of Zhongshan University, Guangzhou; Tianjin Cancer Hospital, Tianjin; Henan Cancer Hospital, Zhengzhou; Harbin Medical University Cancer Hospital, Harbin; Xiangya Hospital Central -South University, Changsha; The Third Affiliated Hospital of Peking University, Beijing; Hebei Cancer Hospital, Shijiazhuang.
P4-12-18 BOLERO-3: Quality-of-life maintained in patients with metastatic breast cancer treated with everolimus plus trastuzumab plus vinorelbine
Isaacs C, Ozguroglu M, Jerusalem G, Xu B, Láng I, O'Regan R, White M, Fasolo A, Litton J, Toi M, Shen K, Andre F, Vuylsteke P, Zhang Y, Zhang J, Taran T, Wilks S. Georgetown University, Washington, DC; Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey; CHU Sart Tilman Liege, Liege, Belgium; Chinese Academy of Medcical Sciences & Peking Union Medical College, Beijing, China; National Institute of Oncology, Budapest, Hungary; Winship Cancer Institute of Emory University, Atlanta, GA; San Raffaele Cancer Center, Milano, Italy; The University of Texas MD Anderson Cancer Center, Houston, TX; Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai City, China; Kyoto University, Kyoto, Japan; Institut Gustave Roussy, Villejuif, France; Clinique et Maternité Sainte Elisabeth, Namur, Belgium; Novartis Pharmaceuticals, East Hanover, NJ; Clinique et Maternite Sainte Elisabeth, Namur, Belgium; Cancer Care Centers of South Texas, San Antonio, TX; Monash Health, East Bentleigh, Victoria, Australia.
P4-12-19 BOLERO-3: Everolimus plus trastuzumab and vinorelbine in Asian patients with HER2-positive metastatic breast cancer
Toi M, Masuda N, Andre F, Ishiguro H, Fasolo A, Xu B, Jerusalem G, Shen K, Wilks S, O'Regan R, Isaacs C, Zhang Y, Taran T, Yap Y-S. Kyoto University, Kyoto, Japan; NHO Osaka National Hospital, Osaka, Japan; Institut Gustave Roussy, Villejuif, France; Kyoto University Hospital, Kyoto University Cancer Center, Kyoto, Japan; San Raffaele Cancer Center, Milan, Italy; Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; CHU Sart Tilman Liege, Liege, Belgium; Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai City, China; Cancer Care Center of South Texas, TX; Winship Cancer Institute of Emory University, Atlanta, GA; Georgetown University, Washington, DC; Novartis Pharmaceuticals, East Hanover, NJ; National Cancer Centre Singapore, Singapore, Singapore.
P4-12-20 Clinical outcomes of patients with recurrent HER2-positive breast cancer after exposure to adjuvant trastuzumab
Mullins D'AN, Abdel-Rasoul M, Querry J, Akuma D, Feng A, Shapiro CL, Macrae E. The Ohio State University, Columbus, OH.
P4-12-21 Trastuzumab cardiac toxicity and HER2 polymorphism: A case-control study
Mailliez A, Dumont A, Bonneterre J. Centre Oscar Lambret, Lille, France; Université Lille Nord de France, Lille, France.
P4-12-22 Time to relapse (TTR) is a potential discriminator of clinical outcome in HER2-positive breast cancer (BC) patients (pts) progressing on adjuvant trastuzumab (AdjT)
Di Cosimo S, Serpico D, Porcu L, Fanetti G, Molino L, Torri V, de Braud F. Fondazione IRCCS Istituto Nazionale Tumori; Istituto di Ricerche Farmacologiche "Mario Negri" – IRCCS, Milan, Italy.
P4-12-23 Subcutaneous trastuzumab (Herceptin™) in patients with HER-2 positive early breast cancer: A UK time and motion study in comparison with intravenous formulation
Burcombe R, Chan S, Simcock R, Samanta K, Percival F, Barrett-Lee P. Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, United Kingdom; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, Sussex, United Kingdom; Roche Products Ltd, Welwyn Garden City, United Kingdom; pH Associates Ltd, Marlow, United Kingdom; Velindre Cancer Centre, Cardiff, United Kingdom.
P4-12-24 Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer
Baird RD, Cresti N, Beddowes E, Saggese M, Flynn M, Garcia Corbacho J, Gao F, Lemech C, Donaldson K, Posner J, Kawabata I, Forster M, Arkenau HT, Plummer R, Jodrell D, Spicer J. University of Cambridge, Cambridge, United Kingdom; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom; King's College London, Guy's Hospital, London, United Kingdom; Sarah Cannon Research UK, London, United Kingdom; University College London Cancer Institute, London, United Kingdom; Shionogi & Co. Ltd., Osaka, Japan.
P4-12-25 Randomized phase II study of pre-operative docetaxel, carboplatin with trastuzumab (TCH) and/or/lapatinib (L) in HER-2 positive (H+) breast cancer patients (BC pts). ICORG 10-05
Crown J, Coate L, Keane M, Kennedy J, O'Reilly S, Kelly C, O'Connor M, Duffy K, Martin M, Murphy C, O'Shea T, Moulton B, Egan K, O'Donovan N, Gullo G, Geraghty K, Hennessy B. All-Ireland Co-Operative Oncology Research Group, Dublin 2, Ireland.
P4-12-26 A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801)
Gomez H, Neciosup S, Tosello C, Mano M, Bines J, Ismael G, Santi PX, Pinczowsky H, Neron Y, Fanelli M, Fein L, Sampaio C, Lerzo G, Capo A, Zarba JJ, Blajman C, Varela MS, Martínez-Mesa J, Werutsky G, Barrios CH. Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil.
P4-12-27 Efficacy and safety of trastuzumab emtansine (T-DM1) vs lapatinib plus capecitabine (XL) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and central nervous system (CNS) metastases: Results from a retrospective exploratory analysis of EMILIA
Krop I, Lin N, Blackwell K, Guardino E, Huober J, Lu M, Miles D, Samant M, Welslau M, Diéras V. Dana-Farber Cancer Institute, Boston, MA; Duke University Medical Center; Genentech, Inc.; Breast Center, St. Gallen; Mount Vernon Cancer Center; Medical Office Hematology; Institut Curie.
P4-12-28 HER2-related biomarkers in HER2+ breast cancer patients in Asia Pacific
Kim S-B, Tsang J, Kim T-Y, Yap YS, Cornelio G, Gong G, Paik S, Lee S, Ng T-Y, Park S, Oh H-S, Yau T, Lee SH, Lim JH, Choi Y-J, Lee EM, Park K-H, Do I-G, Yeoh E-M, Ro J. Asan Medical Center, Korea; Queen Mary Hospital, Hong Kong; Seoul National University Hospital, Korea; National Cancer Center, Singapore; San Juan De Dios Hospital, Philippines; Severance Biomedical Research Institute, Yonsei University College of Medicine, Korea; Dong-A University Medical Centre, Korea; Tuen Mun Hospital, Hong Kong; Seoul St. Mary's Hospital, Korea; GangNeung Asan Hospital, Korea; Yonsei University Medical Centre, Korea; Inha University Hospital, Korea; Pusan National University Hospital, Korea; Kosin University Gospel Hospital, Korea; Korea University Anam Hospital, Korea; Samsung Medical Center, Korea; GlaxoSmithKline Pte Ltd, Singapore; National Cancer Center, Korea.
P4-12-29 Assessment of safety and activity in an expanded phase 1 study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced HER2-positive (HER2+) breast cancer
Munster P, Krop IE, Miller K, Dhindsa N, Niyijiza C, Nielsen U, Odueyungbo A, Rajarethinam A, Marande M, Campbell K, Geretti E, Reynolds JG, Hendriks BS, Wickham T, Moyo V, LoRusso P. Helen Diller Family Compreshensive Cancer Center, UCSF, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Inc, Cambridge, MA; Karmanos Cancer Institute, Detroit, MI.
P4-12-30 A bivalent Her2 targeting DARPin with high efficacy against Her2-low and Her2-positive tumors
Dolado I, Fiedler U, Strobel H, Metz C, Stumpp MT, Rojkjaer L. Molecular Partners AG, Schlieren, Zulia, Switzerland.
   
  Treatment: Immunotherapy (Clinical)
P4-13-01 A pilot study of pre-operative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early stage/resectable breast cancer (ESBC)
Diab A, Solomon SB, Comstock C, Maybody M, Sacchini V, Durack J, Blum B, Yuan J, Patil S, Neville D, Sung J, Kotin A, Morris E, Brogi E, Morrow M, Wolchok J, Allison J, Hudis C, Norton L, McArthur H. Memorial Sloan-Kettering Cancer Center, New York, NY; MD Anderson Cancer Center, Huoston, TX.
P4-13-02 Preliminary results for the phase 1 trial of a dual HER2 peptide cancer vaccine in breast and ovarian cancer patients
Berry JS, Trappey AF, Vreeland TJ, Schneble EJ, Clifton GT, Hale DF, Sears AK, Ponniah S, Shumway NM, Mittendorf EA, Peoples GE. San Antonio Military Medical Center, Fort Sam Houston, TX; MD Anderson Cancer Center, Houston, TX.
P4-13-03 Withdrawn
P4-13-04 Autologous dendritic cells vaccines combined with neoadjuvant chemotherapy increase total pCR in stages II-III non-overexpressing HER2 breast cancer patients and induce phenotypic changes in peripheral blood
Santisteban M, López Díaz de Cerio A, García Cenoz M, Martín P, Zubiri L, Sola I, Espinós J, Salgado E, Fernández Hidalgo O, Inogés S. Clínica Universidad de Navarra, Pamplona, Navarra, Spain; Preventive Medicine and Public Health, Pamplona, Navarra, Spain; Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain.
P4-13-05 HLA-A2 is not a prognostic indicator in breast cancer: Implications for cancer vaccine trials
Trappey AF, Berry JS, Vreeland TJ, Guy CT, Diane HF, Alan SK, Erika SJ, Ferrise L, Shumway NM, Papamichail M, Perez SA, Ponniah S, Mittendorf EA, Peoples GE. San Antonio Military Medical Center, San Antonio, TX; Blanchfield Army Community Hospital, Fort Campbell, KY; Cancer Vaccine Development Lab, Bethesda, MD; Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Greece; MD Anderson Cancer Center, Houston, TX
P4-13-06 Ligation of dectin-1 on tumor infiltrating dendritic cells promotes breast cancer rejection
Wu T-C. Baylor Institute for Immunology Research, Dallas, TX.
   
  Treatment: Antiangiogenic Therapy
P4-14-01 A time course study of genomic instability in breast cancer patients receiving neoadjuvant therapy with or without bevacizumab
Møller EK, Moen Vollan HK, Nord S, von der Lippe Gythfeldt H, Edvardsen H, Silwal-Pandit L, Krohn M, Fleischer T, Schlitchting E, Borgen E, Garred Ø, Fangberget A, Holmen MM, Skjerven H, Lundgren S, Wist E, Naume B, Børresen-Dale A-L, Kristensen VN, Engebraaten O. Oslo University Hospital, Norway; The KG Jebsen Center for Breast and Cancer Research, University of Oslo, Norway; Oslo University Hospital, Oslo, Norway; St Olavs Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Akershus University Hospital, Lørenskog, Norway; Vestre Viken Hospital Trust, Drammen, Norway.
P4-14-02 Molecular response in breast cancer tumors treated with neoadjuvant chemotherapy with and without bevacizumab: Results from NeoAva - A randomized phase II study
Engebraaten O, Vatske C, Krohn M, Silwal-Pandit L, Moen Vollan HK, Møller EK, Nord S, Fleischer T, Borgen E, Edvardsen H, Garred Ø, Fangberget A, Holmen MM, Schlichting E, Skjerven H, Lundgren S, Wist E, Naume B, Børresen-Dale A-L, Kristensen VN. Oslo University Hospital, Oslo, Norway; University of Oslo, Norway; Section for Breast and Endocrine Surgery, Oslo, Norway; Vestre Viken Hospital Trust, Drammen, Norway; St Olav Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Akershus University Hospital, Lørenskog, Norway; Five3 Genomics, LLC, Santa Cruz, CA; The KG Jebsen Center for Breast Cancer Research, University of Oslo, Norway.
P4-14-03 Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study
Guarneri V, Boni C, Puglisi F, Cagossi K, Piacentini F, Bisagni G, Dieci MV, Barbieri E, Vicini R, Conte P. University of Padova, Istituto Oncologico Veneto IRCCS, Padova, Italy; Azienda Ospedaliera ASMN, IRCCS, Reggio Emilia, Italy; University of Modena and Reggio Emilia, Modena, Italy; University of Udine, Udine, Italy; Ramazzini Hospital, Carpi, Italy.
P4-14-04 AVANTI: A non-interventional study examining the combination of bevacizumab with paclitaxel or capecitabine in metastatic breast cancer
Schneeweiss A, Fett W, Aktas B, Fruehauf S, Grafe A, Jakob A, Foerster F, Müller V. National Center for Tumor Diseases (NCT), Heidelberg, Germany; Onkologische Praxis, Wuppertal, Germany; Universitätsklinikum Essen, Essen, Germany; Paracelsus-Kliniken Osnabrück, Osnabrück, Germany; MVZ Nordhausen, Nordhausen, Germany; Ortenau Klinikum Offenburg, Offenburg, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
P4-14-05 First efficacy and safety results of neoadjuvant chemotherapy combined with bevacizumab in patients with non-metastatic inflammatory breast cancer
Ben Ayed F, Raies H, Lakhoua G, Mezlini A, bachouche w, Maamer M. Tunisian Association Fighting Against Cancer (ATCC), Tunis, Tunisia; Institut Salah Azaiez, Tunis, Tunisia; El Farabi Medical Center, Tunis, Tunisia.
   
  Treatment: Novel Targets and Agents
P4-15-01 Integrin αvβ6 is a therapeutic target for high-risk breast cancer and enhances trastuzumab efficacy
Moore KM, Thomas GJ, Duffy SW, Warwick J, Gabe R, Chou P, Ellis IO, Green AR, Haider S, Brouilette K, Saha A, Vallath S, Bowen R, Chelala C, Eccles DM, Tapper WJ, Thompson AM, Quinlan P, Jordan LB, Gillet C, Brentall A, Violette S, Weinreb P, Kendrew J, Barry ST, Hart IR, Jones JL, Marshall JF. Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom.
P4-15-02 The PI3K inhibitor GDC-0032 enhances the efficacy of standard of care therapeutics in PI3K alpha mutant breast cancer models
Sampath D, Nannini MA, Jane G, Hong R, Parsons KL, Belvin M, Friedman LS, Wallin JJ. Genentech, South San Francisco, CA.
P4-15-03 Proteomic modulation in breast tumors after metformin use: Results from a "window of opportunity" trial
Kalinsky K, Zheng T, Crew KD, Refice S, Feldman SM, Taback B, Hibshoosh H, Su T, Maurer MM, Hershman DL. Columbia University Medical Center, New York, NY.
P4-15-04 Synthesis and characterization of EGFR antibody-mediated tumor targeted "gold nanobombs" for treatment of locally advanced breast cancer
Yook S, Cai Z, Lu Y, Pignol J-P, Winnik MA, Reilly RM. University of Toronto, Toronto, ON, Canada; University of Toronto at Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Toronto General Research Institute, University Health Network, Toronto, ON, Canada.
P4-15-05 Novel targeted therapy for breast cancer chest wall recurrence: Low temperature liposomal doxorubicin and mild local hyperthermia
Rugo HS, Zagar TM, Formenti SC, Vujaskovic Z, Muggia F, O'Connor BM, Myerson RJ, Hsu IC-C, Borys N, Blackwell KL, Dewhirst MW. University of California San Francisco Medical Center, San Francisco, CA; University of North Carolina Hospital, Chapel Hill, NC; New York University Medical Center, New York, NY; University of Maryland Medical Center, Baltimore, MD; Commonwealth Hematology/Oncology PC, Plymouth, MA; Washington University in St. Louis Medical Center, St. Louis, MO; Celsion Corporation, Lawrenceville, NJ; Duke University Medical Center, Durham, NC.
P4-15-06 TMEPAI, a novel drug target in breast cancer therapy and prevention
Singha PK, Pandeswara S, Venkatachalam MA, Saikumar P. University of Texas Health Science Center at San Antonio, San Antonio, TX.
P4-15-07 MicroRNA signature of breast cancer brain metastasis for novel targeted therapies
Sethi S, Ahmad A, Ali-Fehmi R, Mittal S, Dyson G, Sarkar F. Wayne State University, Detroit, MI.
P4-15-08 Discovery of a potent inhibitor of CREB-mediated gene transcription that completely suppresses the growth of triple-negative breast cancer cells
Xiao X, Li B, Xie F, Fan Q, Xue C, Qian D. Oregon Health & Science University, Knight Cancer Institute, Portland, OR.
P4-15-09 An exploratory analysis of inactivation of PI3K/AKT/mTOR signaling pathway using neoadjuvant BKM120 in PI3KCA mutated early breast cancer
Estevez LG, Suarez A, Calvo I, Fernandez-Abad M, Perea S, Hidalgo M. Centro Integral Oncologico Clara Campal, Madrid, Spain; Centro Nacional de Investigaciones Oncológicas, Madrid, Spain.
P4-15-10 Synthesis of targeting pH-responsive drug delivery system for overcoming multi-drug resistance in human breast cancer cells
Li Y, Chang Y, Zhou W, Xu Z, Wang J. Alan G. MacDiarmid Institute of Jilin University, Changchun, Jilin, China; The First Hospital of Jilin University, Changchun; China-Japan Union Hospital of JiLin University.
P4-15-11 Withdrawn
P4-15-12 Rebastinib in combination with eribulin ablates TIE2-expressing macrophages, reduces metastasis, and increases survival in the PyMT metastatic breast cancer model
Smith BD, Leary CB, Kaufman MD, Hood MM, Lu W-P, Turner BA, Vogeti S, Wise SC, Berger MS, Flynn DL. Deciphera Pharmaceuticals LLC, Lawrence, KS.
P4-15-13 Rebastinib in combination with paclitaxel ablates TIE2-expressing macrophages, reduces metastasis, and increases survival in the PyMT metastatic breast cancer model
Smith BD, Leary CB, Kaufman MD, Hood MM, Lu W-P, Turner BA, Vogeti S, Wise SC, Berger MS, Flynn DL. Deciphera Pharmaceuticals LLC, Lawrence, KS.
   
  Treatment: New Drugs and Treatment Strategies
P4-16-01 A novel approach to breast cancer prevention: Exploiting autologous fat grafting for the local delivery of cancer therapeutics
Munster PN, Chen S, Thomas S, Thurn KT, Raha P, Foster R, Irvin C, Sbitany H. University of Calirfornia, San Francisco, San Francisco, CA.
P4-16-02 EF24 targets radiation-induced NFkB-dependent stemness in triple negative breast cancer cells
Ramraj SK, Natarajan M, Aravindan S, Herman TS, Aravindan N. University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of Texas Health Sciences Center at San Antonio, San Antonio, TX; Stephensons Cancer Center, Oklahoma City, OK.
P4-16-03 Effect of doxorubicin and paclitaxel on adipose-derived stem cells and breast cancer cells: Can we incorporate chemotherapy into our reconstructive strategies?
Tsuji W, Chung CW, McLaughlin MM, Valentin JE, Marra KG, Rubin JP. Adipose Stem Cell Center, University of Pittsburgh, Pittsburgh, PA.
P4-16-04 Amrubicin as second- or third-line treatment for patients with HER2-negative metastatic breast cancer (MBC): Final results from a phase II trial of the Sarah Cannon Research Institute (SCRI)
Yardley DA, Barton, Jr J, Raefsky E, Harwin W, Priego V, Inclan A, Miletello G, Hart LL, Shastry M, Finney L, Hainsworth JD, Burris III HA. Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL; Center for Cancer and Blood Disorders, Bethesda, MD; Woodlands Medical Specialists, Pensacola, FL; Hematology/Oncology Clinic, LLP, Baton Rouge, LA.
P4-16-05 Hsp90 inhibition potentiates chemotherapy effectiveness in triple negative breast cancer: Role of glucocorticoid receptor signaling
Agyeman A, Jun W, Proia D, Lee N, Skor M, Conzen S. The University of Chicago, Chicago, IL; Synta Pharmaceuticals Corp, Lexington, MA.
P4-16-06 Histone deacetylases inhibitor SAHA enhances anti-tumor effects of poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in breast cancer cells
Min A, Im S-A, Kim S, Song S-H, Lee K-H, Han S-W, Oh D-Y, Kim T-Y, Bang Y-J. Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; Seoul National University College of Medicine, Seoul, Korea.
P4-16-07 Mesenchymal-epithelial transition (MET) and epithelial-mesenchymal transition (EMT) are closely related to chemotherapy resistance of triple negative breast cancer
Deng X, He J, Chang HR. University of California Los Angeles, Los Angeles, CA.
P4-16-08 Neoadjuvant depot hydroxy-progesterone and vitamin D3 in large operable and locally advanced breast cancer: Planned safety and response analysis of a phase III randomized controlled trial
Parmar V, Nair NS, Hawaldar R, Vanamali V, Gupta S, Shet T, Badwe RA. Tata Memorial Hospital, Mumbai, Maharashtra, India.
P4-16-09 Phase 1b/2 trial of the HER3 inhibitor patritumab (U3-1287) in combination with trastuzumab plus paclitaxel in newly-diagnosed patients with HER2+ metastatic breast cancer (MBC)
Carraro S, Campos D, Copigneaux C, Saintilien C, Beckman RA, Korbenfeld E, Coppola MP, Halabe K, Cazap E. Clinical Research Institute, Latin American & Caribbean Society of Medical Oncology (SLACOM), Buenos Aires, Argentina; Daiichi Sankyo Pharma Development, Edison, NJ.
P4-16-10 A novel paclitaxel-dendrimer conjugate demonstrates better efficacy in breast cancer models
Satsangi A, Roy SS, Satsangi RK, Vadlamudi RK, Ong JL. University of Texas at San Antonio, San Antonio, TX; University of Texas Health Science Center at San Antonio, San Antonio, TX; RANN Research Corporation, San Antonio, TX.
P4-16-11 Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors including breast cancer
Masuda N, Mukai H, Ishiguro H, Mitsuma A, Shibata T, Yamamura J, Toi M, Watabe A, Sarashina A, Ebisawa R, Uttenreuther-Fischer M, Ando Y. Osaka National Hospital, Osaka, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Kyoto University Hospital, Kyoto, Japan; Nagoya University Hospital, Nagoya, Japan; Sakai City Hospital, Osaka, Japan; Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan; Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany.
P4-16-12 CARE: A pilot study of the effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in breast cancer patients
de Groot S, Vreeswijk MPG, Gravesteijn G, Boei JJWA, Jochems A, Houtsma D, Nortier HWR, van der Hoeven KJM, Pijl H, Kroep JR. LUMC, Leiden, Zuid- Holland, Netherlands.
   
  Treatment: Clinical Trials Design and Management
P4-17-01 Withdrawn
P4-17-02 Guidelines for the definitions of time-to-event endpoints in randomized clinical trials: Results of the datecan project for breast group
Gourgou-Bourgade S, Dabakuyo-Yonli S, Cameron D, Cardoso F, Poortmans P, Asselain B, Azria D, for DATECAN Group. Institut du Cancer de Montpellier, Montpellier, France; Centre Georges-François Leclerc, Dijon, France; Western General Hospital, Edinburgh, United Kingdom; Champalimaud Cancer Center, Lisbon, Portugal; Institute Verbeeten, Tilburg, Netherlands; Institut Curie, Paris, France; for DATECAN Group, France, Metropolitan.
   
  Treatment: Research Resources - Patients
P4-18-01 Sharing clinical trial results with patient participants: A project of the Dana Farber/Harvard Cancer Center (DF/HCC) breast cancer research advocacy group
Frank ES, Price KN, Colten ME, Fax RG, Levine MA, Matyka C, Dowton AA, Barry WT, Winer EP, Partridge AH. Dana Farber Cancer Institute, Boston, MA; DF/HCC Breast Cancer Program Breast Cancer Advocacy Group, Boston, MA.
   
  Treatment: Research Resources - Tissue and Data Banks
P4-19-01 Attitudes of medical oncologists towards research biopsies
Seah DSE, Scott SM, Guo H, Najita J, Lederman R, Frank E, Sohl J, Kronwitz C, Stadler ZK, Silverman SG, Peppercorn J, Winer EP, Come SE, Lin NU. Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deconess Medical Center, Boston, MA; Brigham and Women's Hospital, Boston, MA; Duke University School of Medicine, Durham, NC; Memorial Sloan-Kettering Cancer Center, New York, NY.
P4-19-02 Early experience of patient donation and researcher use of tissues donated to a national breast cancer tissue bank
Speirs V, Good R, Hanby A, Matharoo-Ball B, Thomson B, Ellis I, Quinlan P, Lyons D, Coates P, Purdie C, Jordan L, Chelala C, Smith S, Ekbote U, Jones L. University of Leeds, United Kingdom; Nottingham Health Science Biobank, United Kingdom; University of Dundee, United Kingdom; Barts Cancer Institute, United Kingdom.
P4-19-03 Breast cancer oriented biobank and associated biobank management system: Preliminary analysis on 9043 samples from 274 individuals
Margossian A, May M, Gutierrez C, Saadjian H, Barchuk S, Vidal L, Truong A, Rodan S, Margossian J, Scheurer M. Breast Center, Buenos Aires, Caba, Argentina; Baylor College of Medicine, Houston, TX.
P4-19-04 Biobank management and tracking web-based system for a breast cancer oriented biobank v2.0: Preliminary analysis
Margossian A, Saadjian H, Mira A, Bacigalupo S, Arzeno A, Thompson M, Margossian M, May M, Barchuk S, Vidal L, Scheurer M, Gutierrez C. Breast Center, Buenos Aires, Caba, Argentina; Baylor College of Medicine, Breast and Cancer Center, Houston, TX.
P4-19-05 Breast cancer campaign tissue bank human cell culture programme: Generating new biomaterials for breast research
Gomm JJ, Smith SG, Allen MD, Morgan AS, Haywood LA, Sarper M, Dreger S, Ironside A, Cortes Lopez EJ, Del Rio Hernandez A, Speirs V, Jones LJ. Barts Cancer Institute, London, United Kingdom; Breast Cancer Campaign Tissue Bank, London, United Kingdom; Independent Cancer Patient's Voice, UK, United Kingdom; Leeds Institute of Cancer & Pathology, Leeds, Yorkshire, United Kingdom; Imperial College, London, United Kingdom.
   
 
Home | About SABCS | Press Releases | Media | Event Photos | Past Symposia | Satellite Symposia | Patient Advocates | FAQs | Contact Us
Registration | Hotel | Support & Exhibits | 2014 Overview | Program | Travel & Transportation

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio

7979 Wurzbach Road, MC 8224 San Antonio, TX 78229 USA
Phone: 210-450-1550    Fax: 210-450-1560    Email: sabcs@uthscsa.edu
       line
Copyright © 2014 SABCS. All rights reserved. - Privacy Policy